Please take a look in the Documents and Downloads - Reports section of the website where you will find Dr O'Briens report form ASH 2009. It summarises they key abstracts and includes all the others if you want to dig deeper. You can also see the abstracts on line by following the links below.

After a decade of imatinib:

http://ash.confex.com/ash/2009/webprogram/Session1761.html

New molecular mechanisms in CML http://ash.confex.com/ash/2009/webprogram/Session2085.html

Prognostic factors

http://ash.confex.com/ash/2009/webprogram/Session2089.html

Managing resistance

http://ash.confex.com/ash/2009/webprogram/Session2090.html

New insights

http://ash.confex.com/ash/2009/webprogram/Session2086.html

New trends in management

http://ash.confex.com/ash/2009/webprogram/Session2091.html

Keep an eye on the SPIRIT 2 website for further updates on CML as they emerge. There will probably be new data coming out at ASCO (4th June 2010).